Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› New York
Clinical trial register · United States · industry-sponsored

Clinical Trials in New York, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 65 Florida 54 New York 35 Illinois 32 Arizona 27
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca86 Janssen Research & Development, LLC53 Pfizer50 Novartis Pharmaceuticals48 Merck Sharp & Dohme LLC39 Clear sponsor filter
State
California65 Florida54 New York35 Illinois32 Arizona27
All 46 states
Target enrolment
to

Trials with a site in New York

35 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Regeneron Pharmaceuticals
Phase 3
1,600
Florida, New York, Texas
2026-08-26
Recruiting
Regeneron Pharmaceuticals
Phase 2
360
Alabama, California, Florida, Illinois, Kansas, Kentucky, New York, South Carolina
2026-07-28
Recruiting
Regeneron Pharmaceuticals
Phase 3
270
Arizona, Georgia, Massachusetts, Michigan, Minnesota, Missouri, New York, Ohio
2026-05-21
Recruiting
Regeneron Pharmaceuticals
Phase 2
120
California, Florida, Georgia, Illinois, Kentucky, Michigan, Nebraska, New York
2026-04-14
Recruiting
Regeneron Pharmaceuticals
Phase 3
1,120
Florida, New York, Texas
2026-03-09
Recruiting
Regeneron Pharmaceuticals
Phase 3
915
Georgia, New York, Ohio, Texas
2026-01-02
Recruiting
Regeneron Pharmaceuticals
Phase 3
20
Arizona, California, Colorado, Georgia, Massachusetts, New York, North Carolina, Pennsylvania
2025-11-10
Active, closed
Regeneron Pharmaceuticals
Phase 2
19
New York
2024-09-30
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
240
California, Connecticut, Illinois, Michigan, New York, North Carolina, Pennsylvania, Texas
2024-09-23
Recruiting
Regeneron Pharmaceuticals
Phase 2
116
Maryland, Massachusetts, Michigan, New York, Pennsylvania, Washington
2024-09-16
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
220
California, Colorado, Massachusetts, Michigan, New York, Ohio, Tennessee, Texas
2024-08-07
Recruiting
Regeneron Pharmaceuticals
Phase 1
90
Massachusetts, New Jersey, New York, Pennsylvania, Utah
2024-08-06
Active, closed
Regeneron Pharmaceuticals
Phase 2
195
Florida, Illinois, Kansas, Michigan, Missouri, New York, Oregon, Virginia
2024-07-16
Active, closed
Regeneron Pharmaceuticals
Phase 1
6
Florida, Georgia, Massachusetts, New York, Pennsylvania
2024-05-17
Active, closed
Regeneron Pharmaceuticals
Observational
1,000
New York
2024-02-21
Recruiting
Regeneron Pharmaceuticals
Phase 3
580
California, Florida, Indiana, Mississippi, New Hampshire, New York, Wisconsin
2023-12-28
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
149
California, Colorado, Kentucky, Michigan, New Jersey, New York, North Carolina, Texas
2023-12-19
Recruiting
Regeneron Pharmaceuticals
Phase 3
822
Arizona, California, Indiana, Massachusetts, Michigan, Mississippi, New York, North Carolina
2023-12-12
Recruiting
Regeneron Pharmaceuticals
Observational
20
California, Connecticut, Illinois, Maryland, Minnesota, New York, Pennsylvania
2023-10-19
Recruiting
Regeneron Pharmaceuticals
Phase 3
410
California, Florida, Kentucky, New York, North Carolina, Oregon, Texas, Washington
2023-09-18
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
36
California, Florida, Massachusetts, New York, Ohio, Washington, Wisconsin
2023-06-27
Active, closed
Regeneron Pharmaceuticals
Phase 2
51
California, Kentucky, New Mexico, New York, North Carolina, Texas, Virginia, Washington
2023-04-21
Recruiting
Regeneron Pharmaceuticals
Phase 1
107
California, Kentucky, Massachusetts, New Jersey, New York, Texas
2023-04-20
Active, closed
Regeneron Pharmaceuticals
Phase 3
1,564
California, Colorado, Florida, Illinois, Massachusetts, Michigan, New Jersey, New York
2023-01-16
Recruiting
Regeneron Pharmaceuticals
Phase 1
317
California, Georgia, Indiana, Massachusetts, Michigan, Minnesota, New York, North Carolina
2022-08-17
Active, closed
Regeneron Pharmaceuticals
Phase 1/2
43
California, Connecticut, District of Columbia, Illinois, Maryland, Minnesota, New York, Pennsylvania
2022-08-02
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
228
California, Connecticut, Kentucky, Maryland, New Jersey, New York, North Carolina, Ohio
2021-11-30
Active, closed
Regeneron Pharmaceuticals
Observational
100
California, New York, Ohio, Rhode Island, Texas, West Virginia
2021-02-05
Active, closed
Regeneron Pharmaceuticals
Phase 1/2
548
California, Colorado, Florida, Illinois, Iowa, Michigan, New Jersey, New York
2020-12-21
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
612
California, Florida, Illinois, Massachusetts, Michigan, New York, Ohio, Pennsylvania
2020-12-08
Active, closed
Regeneron Pharmaceuticals
Phase 1/2
95
California, District of Columbia, Florida, Massachusetts, New York, Pennsylvania, Texas
2020-01-07
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Illinois, Iowa, Kentucky, Massachusetts, Minnesota, New Jersey, New York, North Carolina
2019-11-13
Active, closed
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
NCT03916627Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma
DrugsFianlimab·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
65
New York
2019-07-23
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
387
Florida, Georgia, Indiana, Kentucky, Michigan, New Jersey, New York, Ohio
2019-01-23
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
890
Alabama, Massachusetts, Minnesota, New York, Ohio, Oklahoma, Tennessee, Texas
2018-05-21
Rows per page Showing 1–35 of 35
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-usa/state/new-york

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 11 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 35 of those studies with a site in New York that also match the filters currently applied.

How many clinical trials are recruiting in New York?

23 of the 35 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 12 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (New York), 35 studies
PhaseStudiesRecruitingShare
Phase 1/211831.4%
Phase 39825.7%
Phase 28322.9%
Phase 14311.4%
Observational318.6%

Most active sponsors

Lead sponsors with the most studies (New York)
Lead sponsorStudiesRecruiting
Regeneron Pharmaceuticals3523
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.